As of 2025-10-17, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (36.72) USD. This relative valuation is based on P/E multiples. With the latest stock price at 74.97 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -149.0%.
The range of the Relative Valuation is (35.70) - (40.67) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 18.7x | 16.1x |
| Forward P/E multiples | 16.4x - 19.0x | 17.6x |
| Fair Price | (35.70) - (40.67) | (36.72) |
| Upside | -147.6% - -154.2% | -149.0% |
| Date | P/E |
| 2025-10-16 | -34.40 |
| 2025-10-15 | -34.39 |
| 2025-10-14 | -32.04 |
| 2025-10-13 | -32.27 |
| 2025-10-10 | -32.18 |
| 2025-10-09 | -32.29 |
| 2025-10-08 | -32.00 |
| 2025-10-07 | -31.39 |
| 2025-10-06 | -31.07 |
| 2025-10-03 | -29.90 |
| 2025-10-02 | -26.97 |
| 2025-10-01 | -26.31 |
| 2025-09-30 | -27.27 |
| 2025-09-29 | -26.65 |
| 2025-09-26 | -25.83 |
| 2025-09-25 | -25.42 |
| 2025-09-24 | -25.36 |
| 2025-09-23 | -25.53 |
| 2025-09-22 | -25.53 |
| 2025-09-19 | -25.24 |
| 2025-09-18 | -24.79 |
| 2025-09-17 | -23.72 |
| 2025-09-16 | -23.22 |
| 2025-09-15 | -22.75 |
| 2025-09-12 | -22.65 |
| 2025-09-11 | -23.80 |
| 2025-09-10 | -24.93 |
| 2025-09-09 | -25.92 |
| 2025-09-08 | -26.10 |
| 2025-09-05 | -26.44 |
| 2025-09-04 | -26.35 |
| 2025-09-03 | -26.48 |
| 2025-09-02 | -26.88 |
| 2025-08-29 | -26.88 |
| 2025-08-28 | -26.69 |
| 2025-08-27 | -26.53 |
| 2025-08-26 | -27.00 |
| 2025-08-25 | -25.97 |
| 2025-08-22 | -26.27 |
| 2025-08-21 | -25.95 |
| 2025-08-20 | -25.42 |
| 2025-08-19 | -24.64 |
| 2025-08-18 | -25.06 |
| 2025-08-15 | -24.87 |
| 2025-08-14 | -24.84 |
| 2025-08-13 | -24.19 |
| 2025-08-12 | -23.57 |
| 2025-08-11 | -22.97 |
| 2025-08-08 | -21.96 |
| 2025-08-07 | -22.00 |